Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Charles River Laboratories on Its Acquisition of WIL Research
Davis Polk is advising Charles River Laboratories International, Inc. on its acquisition of WIL Research for approximately …
Davis Polk Advises China Cinda on a Strategic Investment by Sino Biopharmaceutical
Davis Polk is advising China Cinda Asset Management Co., Ltd. (“China Cinda”) in connection with a proposed strategic…
Mylan N.V. $1 Billion Notes Offering
Davis Polk advised the representatives of the initial purchasers on two Rule 144A/Regulation S offerings by Mylan N.V. of …
Mindray Medical Going-Private Transaction
Davis Polk is advising Lazard Asia (Hong Kong) Limited as financial adviser to the special committee of the board of…
Davis Polk Advises Penumbra, Inc. on Its $138 Million Initial Public Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an…
Davis Polk Wins Summary Judgment of Non-Infringement in Patent Litigation on Behalf of Transcend Medical, Inc.
Davis Polk represents Transcend Medical, Inc., an innovator in the field of Micro-Invasive Glaucoma Surgery, in a patent…
Davis Polk Advises Fujian Thai Hot Investment on Its Purchase of a Majority Interest in Alliance HealthCare Services
Davis Polk is advising Fujian Thai Hot Investment Co., Ltd in connection with its purchase of approximately 51.5% of the…
Seattle Genetics, Inc. $552 Million Equity Offering
Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415…
Biogen Inc. $6 Billion Senior Notes Offering
Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal…
Davis Polk Advises RoundTable Healthcare Partners on the Formation of Its Equity Fund IV and Capital Fund III
Davis Polk advised RoundTable Healthcare Partners (“RoundTable”) in connection with the formation of, and the sale of…